Efficacy and Safety of TF002 in Cutaneous Mastocytosis
Condition(s):Cutaneous MastocytosisLast Updated:November 12, 2007Completed
Hide Studies Not Open or Pending
Condition(s):Cutaneous MastocytosisLast Updated:November 12, 2007Completed
Condition(s):Cutaneous MastocytosesLast Updated:March 15, 2023Recruiting
Condition(s):Urticaria Pigmentosa; Cutaneous MastocytosisLast Updated:August 20, 2020Completed
Condition(s):Cutaneous MastocytosisLast Updated:September 25, 2020Unknown status
Condition(s):Cutaneous Mastocytosis; Indolent Systemic MastocytosisLast Updated:July 17, 2019Completed
Condition(s):MastocytosisLast Updated:October 20, 2021Unknown status
Condition(s):Indolent Systemic MastocytosisLast Updated:December 3, 2019Completed
Condition(s):Systemic MastocytosisLast Updated:July 15, 2019Completed
Condition(s):Mast Cell Activation Disease; Mast Cell Activation Syndrome; Mast Cell Disease; Urticaria PigmentosaLast Updated:December 1, 2022Completed
Condition(s):Urticaria PigmentosaLast Updated:December 8, 2008Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.